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Over the last decades an explosive increase in basic endocrine science, especially in molecular genetics, and its translational application to patients had a 
profound impact on endocrine clinical management. In view of this rapid progress 
in endocrinology and metabolism, ABE&M have launched a second special edition 
of “Clinical & Molecular Endocrine (C&M) Case Reports” to attract more physician 
readers to this growing field. In addition, focusing on molecular case reports that were 
followed by different expert groups of all recognized endocrinology subspecialties 
can help ABE&M achieve one of its missions in continuing education, a commitment 
invigorated by the first C&M in 2008 (1).
Most of the molecular medicine approaches were thought to be almost exclusive 
to basic research scientists, but lately these have been progressively extended to 
physicians. On the one hand, the clinical field profits from scientific advances; on the 
other hand, clinical observations frequently nourish questions for further investigation, 
sprouting answers that have important influence on basic science. These molecular 
approaches comprise human DNA, RNA and protein assays envisioning more accurate 
diagnosis or prognosis markers of endocrine genetic disorders, mostly using molecular 
biology tools. Not only may these tools help establish molecular aetiology but also 
broaden the understanding of pathophysiological mechanisms, target individualized 
medication (farmacogenomics), identify primary prevention and pre-natal intervention. 
Undoubtedly, these advances in molecular endocrinology must grow together with 
ethics in view of offering the best possible genetic counseling practice.
In 2008, ABE&M offered the first round of molecular case reports in a way our 
reader would become more interested: how to take care of a patient in face of a 
particular molecular diagnosis. Proudly, C&M 2008 has been showing great scientific 
repercussion worldwide. These peer-reviewed original articles were cited by many 
different international endocrine Journals, as many as 75%. For instance, the work 
of Piccoli and cols., 2008 has been cited 5 times within two years (2). In general, 
we observed that the last edition reached 1.5 citation per article, a performance 50% 
greater than other editions in the same period. Several other articles received 3 or 4 
citations and deserve our recognition (3-9). 
 Among the articles cited abroad within the same period, 8 were referenced more 
than 3 times, which is a promising sign of ABE&M’s most recent growth. We hope we 
will continuously thrive – a challenge beyond any ulterior interest and that strongly relies 
on the commitment of ABE&M editorial members, authors, and particularly reviewers. 
We welcome you with the C&M2010 to get the best of the following 17 peer-
reviewed articles and 1 review (10), reassuming our mission of bringing basic science 
and physician investigators together; therefore, translating these findings to better 
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assist our patients. The articles are diverse and reflect 
the maturity and expertise of our scientists who have 
provided their best resources of molecular diagnosis 
and assistance to patients. 
We would like to express our deep gratitude to the 
authors, who submitted their reports, to the reviewers, 
who carefully pointed out opportunities for improve-
ment, to the ABE&M office coworkers and editing 
board, who have given their best to meet the highest 
standards. We also hope our readers will agree and take 
advantage of these following readings.
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